Breaking News: NIH Announces Results of ME/CFS Program Awards
The National Institutes of Health (NIH) announced today the outcome of its ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) competitive consortium grants, marking an unprecedented and tangible commitment from the federal agency to the disease.
The NIH announced four recipient teams; one Data Management Coordination Center (DMCC) and three Collaborative Research Centers (CRCs).
The team selected to lead the development of the Data Management Coordination Center (DMCC) will serve as the keystone to centralize, share and standardize the data of the ME/CFS Collaborative Research Centers.
- Dr. Rick Williams (RTI International) in partnership with Dr. Peter Rowe (Johns Hopkins School of Medicine (JHSM)) and Dr. Zaher Nahle (SMCI).
The three teams selected to lead the development of the Collaborative Research Centers (CRCs) represent an incredible breadth and depth of expertise from prestigious institutions.
- Dr. Ian Lipkin (Columbia University) and team, with SMCI as collaborator
- Dr. Maureen Hanson (Cornell University) and team, with SMCI as a collaborator
- Dr. Derya Unutmaz (the Jackson Laboratory for Genomic Medicine (JAX) ) and team.
Since the funding announcement was released in January, the ME/CFS community has waited anxiously to hear the results for this new era of ME/CFS research. The response to the NIH grant solicitations was strong, attracting high caliber applicants. These submissions included expertise in immunity, inflammation, neuroendocrine biology, bioenergetics, epidemiology, biostatistics, clinical care, and clinical management, some of whom were applying their talent for the first time in the ME/CFS field.
The Solve ME/CFS Initiative (SMCI) was honored participate in seven proposals during the application process. It was a privilege to work with diverse applicants, all of whom embody of our organization’s mission to make ME/CFS
understood,
diagnosable, and
treatable. We serve as a credible scientific partner and a trusted resource for everyone who is creating value in our disease space. We will continue to maintain and pursue those collaborations with proposals that were not funded, in addition to our role with the NIH-funded centers.1